Genomics company WuXi NextCODE raises $75mm in Series B capital; later raises additional $165mm

WuXi NextCODE Genomics (contract genomics) raised $75mm in its Series B financing round co-led by Temasek and Yunfeng Capital with participation from Amgen Ventures and 3W Partners. The firm will use the proceeds to advance the commercialization of its consumer offerings for the China market, to strengthen its global leadership position in informatics, and to expand its artificial intelligence and deep learning capabilities. The company was formed in January 2015 when WuXi PharmaTech acquired genomics company NextCODE Health. Earlier this year WuXi NextCODE entered into a 15-year collaboration with AbbVie Inc. and Genomics Medicine Ireland to perform population genomics research in Ireland with the goal of discovering and developing new therapies for diseases in the areas of oncology, neuroscience, and immunology.